Compare Enbridge Inc (ENB) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Cassava Sciences Inc — how do they compare? Enbridge Inc trades at $51.58 (market cap $112.62B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Enbridge Inc is far larger — about 2358.5× Cassava Sciences Inc's market cap, and Enbridge Inc pays a 5.34% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ENB | FLNA | |
|---|---|---|
Market Cap | $112.62B | $47.75M |
Sector | Energy | Health |
52-Week High | $58.04 | $4.64 |
52-Week Low | $45.23 | $0.87 |
Enterprise Value | $196.53B | -$34.93M |
Dividend Yield | 5.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $51.51, up 0.23% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend history with 31 consecutive years of increases. Revenue grew to $65.19B in 2025, though net income margin is expected to dip to 7.33% in 2026. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook is mixed: robust infrastructure demand and a $41B project backlog support growth, but legal challenges and volatile energy markets pose risks. The stock offers a solid yield and consistent dividend growth, appealing for income investors, yet faces headwinds from regulatory scrutiny and debt levels nearing 49% of assets.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
